IL-12 directs further maturation of ex vivo differentiated NK cells with improved therapeutic potential

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Lehmann, Dorit ^a   Spanholtz, Jan ^b   Sturtzel, Caterina ^a   Tordoir, Marleen ^b   Schlechta, Bernhard ^c   Groenewegen, Dirk ^b   Hofer, Erhard ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Glycostem Therapeutics   (Netherlands)

^c UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CD161 ANTIGEN; CD33 ANTIGEN; CD56 ANTIGEN; GAMMA INTERFERON; INHIBITOR OF DIFFERENTIATION 3; INTERLEUKIN 12; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; L SELECTIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NATURAL KILLER CELL RECEPTOR NKG2A; RITUXIMAB; TRANSCRIPTION FACTOR GATA 3;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CELL DIFFERENTIATION; CELL MATURATION; CELL POPULATION; CELL SELECTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; DOWN REGULATION; DRUG MECHANISM; EX VIVO STUDY; HUMAN; HUMAN CELL; NATURAL KILLER CELL; PROTEIN EXPRESSION; UPREGULATION;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; FETAL BLOOD; FLOW CYTOMETRY; GATA3 TRANSCRIPTION FACTOR; HEMATOPOIETIC STEM CELLS; HIGH MOBILITY GROUP PROTEINS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INHIBITOR OF DIFFERENTIATION PROTEINS; INTERLEUKIN-2; K562 CELLS; KILLER CELLS, NATURAL; L-SELECTIN; NEOPLASM PROTEINS; RECEPTORS, CCR6; RECEPTORS, CXCR3; RECEPTORS, IGG; RECEPTORS, KIR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84900332725     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087131     Document Type: Article

References (47)

1. Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, et al. (2001) Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood 97: 3146-3151.
2. Cooper MA, Fehniger TA, Caligiuri MA (2001) The biology of human natural killer-cell subsets. Trends Immunol 22: 633-640. (Pubitemid 33043908)
3. Di Santo JP (2008) Natural killer cells: diversity in search of a niche. Nat Immunol 9: 473-475.
4. Moretta L (2010) Dissecting CD56dim human NK cells. Blood 116: 3689-3691.
5. Romagnani C, Juelke K, Falco M, Morandi B, D'Agostino A, et al. (2007) CD56brightCD16- killer Ig-like receptor- NK cells display longer telomeres and acquire features of CD56dim NK cells upon activation. J Immunol 178: 4947-4955. (Pubitemid 46595277)
6. Berahovich RD, Lai NL, Wei Z, Lanier LL, Schall TJ (2006) Evidence for NK cell subsets based on chemokine receptor expression. J Immunol 177: 7833-7840. (Pubitemid 44846299)
7. Morandi F, Ferretti E, Castriconi R, Dondero A, Petretto A, et al. (2011) Soluble HLA-G dampens CD94/NKG2A expression and function and differentially modulates chemotaxis and cytokine and chemokine secretion in CD56bright and CD56dim NK cells. Blood 118: 5840-5850.
8. Robertson MJ (2002) Role of chemokines in the biology of natural killer cells. J Leukoc Biol 71: 173-183.
9. Trinchieri G, Gerosa F (1996) Immunoregulation by interleukin-12. J Leukoc Biol 59: 505-511. (Pubitemid 26155295)
10. McDyer JF, Wu CY, Seder RA (1998) The regulation of IL-12: its role in infectious, autoimmune, and allergic diseases. J Allergy Clin Immunol 102: 11-15. (Pubitemid 28345777)
11. Loza MJ, Perussia B (2004) The IL-12 signature: NK cell terminal CD56+high stage and effector functions. J Immunol 172: 88-96. (Pubitemid 38020459)
12. Saez-Borderias A, Romo N, Magri G, Guma M, Angulo A, et al. (2009) IL-12-dependent inducible expression of the CD94/NKG2A inhibitory receptor regulates CD94/NKG2C+ NK cell function. J Immunol 182: 829-836.
13. Ljunggren HG, Malmberg KJ (2007) Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol 7: 329-339.
14. Sutlu T, Alici E (2009) Natural killer cell-based immunotherapy in cancer: current insights and future prospects. J Intern Med 266: 154-181.
15. Lehmann D, Spanholtz J, Osl M, Tordoir M, Lipnik K, et al. (2012) Ex vivo generated natural killer cells acquire typical natural killer receptors and display a cytotoxic gene expression profile similar to peripheral blood natural killer cells. Stem Cells Dev 21: 2926-2938.
16. Spanholtz J, Preijers F, Tordoir M, Trilsbeek C, Paardekooper J, et al. (2011) Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process. PLoS One 6: e20740.
17. Spanholtz J, Tordoir M, Eissens D, Preijers F, van der Meer A, et al. (2010) High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy. PLoS One 5: e9221.
18. Bhat R, Watzl C (2007) Serial killing of tumor cells by human natural killer cells-enhancement by therapeutic antibodies. PLoS One 2: e326.
19. Bremer E, ten Cate B, Samplonius DF, Mueller N, Wajant H, et al. (2008) Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonists. Cancer Res 68: 597-604. (Pubitemid 351380089)
20. Niederleithner H, Heinz M, Tauber S, Bilban M, Pehamberger H, et al. (2012) Wnt1 is anti-lymphangiogenic in a melanoma mouse model. J Invest Dermatol 132: 2235-2244.
21. Wojta J, Hoover RL, Daniel TO (1989) Vascular origin determines plasminogen activator expression in human endothelial cells. Renal endothelial cells produce large amounts of single chain urokinase type plasminogen activator. J Biol Chem 264: 2846-2852. (Pubitemid 19057779)
22. Blomberg K, Granberg C, Hemmila I, Lovgren T (1986) Europium-labelled target cells in an assay of natural killer cell activity. I. A novel non-radioactive method based on time-resolved fluorescence. J Immunol Methods 86: 225-229. (Pubitemid 16146649)
23. Eissens DN, Spanholtz J, van der Meer A, van Cranenbroek B, Dolstra H, et al. (2012) Defining early human NK cell developmental stages in primary and secondary lymphoid tissues. PLoS One 7: e30930.
24. Barton K, Muthusamy N, Fischer C, Ting CN, Walunas TL, et al. (1998) The Ets-1 transcription factor is required for the development of natural killer cells in mice. Immunity 9: 555-563. (Pubitemid 28499206)
25. Billot K, Parizot C, Arrouss I, Mazier D, Debre P, et al. (2009) Differential aiolos expression in human hematopoietic subpopulations. Leuk Res 34: 289-293.
26. Colucci F, Caligiuri MA, Di Santo JP (2003) What does it take to make a natural killer? Nat Rev Immunol 3: 413-425. (Pubitemid 37323201)
27. Gascoyne DM, Long E, Veiga-Fernandes H, de Boer J, Williams O, et al. (2009) The basic leucine zipper transcription factor E4BP4 is essential for natural killer cell development. Nat Immunol 10: 1118-1124.
28. Heemskerk MH, Blom B, Nolan G, Stegmann AP, Bakker AQ, et al. (1997) Inhibition of T cell and promotion of natural killer cell development by the dominant negative helix loop helix factor Id3. J Exp Med 186: 1597-1602. (Pubitemid 27479820)
29. Ikawa T, Fujimoto S, Kawamoto H, Katsura Y, Yokota Y (2001) Commitment to natural killer cells requires the helix-loop-helix inhibitor Id2. Proc Natl Acad Sci U S A 98: 5164-5169. (Pubitemid 32397100)
30. Marusina AI, Kim DK, Lieto LD, Borrego F, Coligan JE (2005) GATA-3 is an important transcription factor for regulating human NKG2A gene expression. J Immunol 174: 2152-2159. (Pubitemid 40223959)
31. Morgan B, Sun L, Avitahl N, Andrikopoulos K, Ikeda T, et al. (1997) Aiolos, a lymphoid restricted transcription factor that interacts with Ikaros to regulate lymphocyte differentiation. EMBO J 16: 2004-2013. (Pubitemid 27170961)
32. Samson SI, Richard O, Tavian M, Ranson T, Vosshenrich CA, et al. (2003) GATA-3 promotes maturation, IFN-gamma production, and liver-specific homing of NK cells. Immunity 19: 701-711. (Pubitemid 37490795)
33. Tayade C, Fang Y, Black GP, V AP, Jr., Erlebacher A, et al. (2005) Differential transcription of Eomes and T-bet during maturation of mouse uterine natural killer cells. J Leukoc Biol 78: 1347-1355. (Pubitemid 41779241)
34. Yun S, Lee SH, Yoon SR, Kim MS, Piao ZH, et al. (2010) TOX regulates the differentiation of human natural killer cells from hematopoietic stem cells in vitro. Immunol Lett 136: 29-36.
35. Loza MJ, Perussia B (2001) Final steps of natural killer cell maturation: a model for type 1-type 2 differentiation? Nat Immunol 2: 917-924. (Pubitemid 32976163)
36. Takahashi E, Kuranaga N, Satoh K, Habu Y, Shinomiya N, et al. (2007) Induction of CD16+ CD56bright NK cells with antitumour cytotoxicity not only from CD16- CD56bright NK Cells but also from CD16- CD56dim NK cells. Scand J Immunol 65: 126-138. (Pubitemid 46174920)
37. Beziat V, Duffy D, Quoc SN, Le Garff-Tavernier M, Decocq J, et al. (2011) CD56brightCD16+ NK cells: a functional intermediate stage of NK cell differentiation. J Immunol 186: 6753-6761.
38. Juelke K, Killig M, Luetke-Eversloh M, Parente E, Gruen J, et al. (2010) CD62L expression identifies a unique subset of polyfunctional CD56dim NK cells. Blood 116: 1299-1307.
39. Irjala H, Johansson EL, Grenman R, Alanen K, Salmi M, et al. (2001) Mannose receptor is a novel ligand for L-selectin and mediates lymphocyte binding to lymphatic endothelium. J Exp Med 194: 1033-1042.
40. Marttila-Ichihara F, Turja R, Miiluniemi M, Karikoski M, Maksimow M, et al. (2008) Macrophage mannose receptor on lymphatics controls cell trafficking. Blood 112: 64-72.
41. Sperandio M, Smith ML, Forlow SB, Olson TS, Xia L, et al. (2003) P-selectin glycoprotein ligand-1 mediates L-selectin-dependent leukocyte rolling in venules. J Exp Med 197: 1355-1363. (Pubitemid 36617782)
42. Tedder TF, Steeber DA, Pizcueta P (1995) L-selectin-deficient mice have impaired leukocyte recruitment into inflammatory sites. J Exp Med 181: 2259-2264.
43. Bennett IM, Zatsepina O, Zamai L, Azzoni L, Mikheeva T, et al. (1996) Definition of a natural killer NKR-P1A+/CD56-/CD16- functionally immature human NK cell subset that differentiates in vitro in the presence of interleukin 12. J Exp Med 184: 1845-1856. (Pubitemid 26404475)
44. Guia S, Cognet C, de Beaucoudrey L, Tessmer MS, Jouanguy E, et al. (2008) A role for interleukin-12/23 in the maturation of human natural killer and CD56+ T cells in vivo. Blood 111: 5008-5016.
45. Galon J, Sudarshan C, Ito S, Finbloom D, O'Shea JJ (1999) IL-12 induces IFN regulating factor-1 (IRF-1) gene expression in human NK and T cells. J Immunol 162: 7256-7262. (Pubitemid 29277698)
46. Yamamoto K, Shibata F, Miyasaka N, Miura O (2002) The human perforin gene is a direct target of STAT4 activated by IL-12 in NK cells. Biochem Biophys Res Commun 297: 1245-1252. (Pubitemid 35216381)
47. Binyamin L, Alpaugh RK, Hughes TL, Lutz CT, Campbell KS, et al. (2008) Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy. J Immunol 180: 6392-6401.